Google is Developing a Nanoparticle System for Biomarker Detection

Andrew Conrad, Head of Life Sciences at Google, announced last week at the Wall Street Journal Digital conference that Google is developing a wearable sensor that can receive signals from circulating nanoparticles. The nanoparticles are bound to antibodies against...

Is Ovarian Cancer Under-Served by Personalized Medicine?

Ovarian cancer is the most fatal gynecological cancer, and among the most fatal of all cancer types. The five year survival rate for ovarian cancer is 44.6%, which (remarkably) is exactly half that of breast cancer. This means that while there are over 10 times as...

Oxford University Makes Huge Investment in Personalized Medicine

Oxford University this week announced the establishment of the Precision Cancer Medicine Institute (PCMI) with an initial investment of over $175 million. This new institute will carry out research into advanced cancer diagnostic and therapeutic techniques, and is...

U.S. Behind the Curve in RAS Mutation Testing

In news from last month’s European Society for Medical Oncology Congress in Madrid, it appears that the United States lags behind the European Union in comprehensiveness of testing for RAS mutations. Experts now agree that expanded RAS testing is needed for...

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access